Testing gene editing techniques in animal models
Official title: Genome Editing and Biological Effects Testing: Somatic Cell Gene Editing Testing
Funded at University of Missouri-Columbia · NIH-10928245 · Data updated 2026-11-12
This study is exploring new gene editing methods using pigs that have health conditions similar to humans, to see if these treatments are safe and effective before they are used in people.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Missouri-Columbia NIH-funded |
| Lab location | 1 site (Columbia, United States) |
| Project start | September 12, 2023 |
| Project end | August 31, 2028 |
| Funding year | 2024 |
| Award (this year) | $810,421 |
| NIH project number | 5U42OD035738-02 |
| Project ID | NIH-10928245 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals with genetic disorders that could potentially be treated with gene editing technologies.
✕Less likely to help
Patients with conditions that are not amenable to gene editing or those who do not have a genetic basis for their condition may not benefit from this research.
What this research studies
This research focuses on developing and testing gene editing techniques using swine models that mimic human conditions. By creating these models, the project aims to evaluate the safety and effectiveness of new therapeutic strategies before they are applied in humans. The research includes detailed procedures for testing and analyzing the outcomes of gene editing technologies, ensuring that data is preserved and communicated effectively. This work is essential for translating basic scientific discoveries into practical clinical applications.
Why it matters
Potential benefit: If successful, this research could lead to safer and more effective gene therapies for various genetic conditions.
How similar studies have gone: Previous research has shown promise in using animal models for testing gene editing techniques, indicating that this approach could be effective.
Where this research is happening
-
University of Missouri-Columbia
Columbia, United States Active
Researchers
- Principal investigator: Green, Jonathan a — University of Missouri-Columbia
- Study coordinator: Green, Jonathan a
Related research
Other NIH-funded projects on the same topics.
-
Boosting immune response to fight cancer
This study is exploring a new way to help your immune system better fight cancer by tweaking certain cells in your body, and it aims to improve treatment for people with advanced cancer.
-
Interface between immune cells and scarring in the eye
This grant looks at how immune cells influence scar formation in the cornea after injury and how this affects vision.
-
Understanding cell-cleanup problems in C9ORF72-related ALS/FTD
Researchers are studying why the body's cell-cleanup systems fail in a genetic form of ALS/FTD to pave the way for better treatments.
-
Molecular clues to endometriosis-related infertility
This grant explores how molecular changes in endometriosis contribute to infertility, with the aim of finding better ways to diagnose and treat the condition.
-
A universal Shigella vaccine using SAVE to protect people of all ages
A new vaccine approach called SAVE aims to prevent Shigella-related dysentery across all ages, including children and adults, by targeting conserved bacterial components.
-
Biomarkers that predict osteoarthritis risk in people at higher risk
A long-term study will look for protein markers in body fluids that could predict who will develop knee osteoarthritis before symptoms appear.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.